Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Bootstrap Analysis of Index Hospital Stay Costs
Performance of 1,000 bootstrap replicates indicates a 94.6% probability of cost savings with bivalirudin monotherapy compared with heparin (unfractionated or low-molecular weight heparin) with upstream glycoprotein IIb/IIIa receptor inhibition (GPI) (yellow line) and a 68.3% probability of lower cost with bivalirudin monotherapy compared with heparin (unfractionated or low molecular weight heparin) and catheterization laboratory (cath lab)-initiated GPI (black line).
|
